Truxima® is the world's first oncology mAB biosimilar developed by Celltrion and approved by FDA and EMA.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.